menu
    • menu
    [{"orgOrder":0,"company":"Samsung Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Dinona"}]

    Find Infections and Infectious Diseases Clinical Drug Pipeline Developments & Deals by Samsung Biologics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tixagevimab,Cilgavimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : AstraZeneca

                            Deal Size : $380.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Samsung Biologics and AstraZeneca Expand Strategic Manufacturing Partnership to Include COVID-19 and Cancer Th...

                            Details : Under the agreement, Samsung Biologics manufactures AstraZeneca’s COVID-19 long-acting antibody, Evusheld, also known as AZD7442 (tixagevimab, cilgavimab), a combination that provides long-lasting protection for up to 12 months in COVID 19 infection.

                            Product Name : Evusheld

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : Tixagevimab,Cilgavimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : AstraZeneca

                            Deal Size : $380.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine

                            Details : Under the terms of the manufacturing services and supply agreement, Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

                            Product Name : mRNA-1273

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 22, 2021

                            Lead Product(s) : TAK-919

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bamlanivimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 ...

                            Details : Lilly’s success in developing neutralizing antibodies against COVID-19, augmented with Samsung Biologics’ manufacturing scale, signals a major move forward in delivering important treatments to patients suffering from the deadly pandemic.

                            Product Name : LY-CoV555

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            November 17, 2020

                            Lead Product(s) : Bamlanivimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNP-019

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Dinona

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Samsung Biologics Inks Development Partnership with Dinona for Potential COVID-19 Treatment

                            Details : Under this agreement, Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

                            Product Name : DNP-019

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 21, 2020

                            Lead Product(s) : DNP-019

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Dinona

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Vir Biotechnology

                            Deal Size : $362.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Samsung Inks $362M Deal To Boost Vir's COVID-19 Antibody Output

                            Details : Through this deal parties are trying to scale up manufacturing of Vir's monoclonal antibody program as a potential treatment for COVID-19.

                            Product Name : VIR-7831

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 04, 2020

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Vir Biotechnology

                            Deal Size : $362.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth